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TransplantationThe kidney transplant is the main therapeutic alternative for end-stage kidney disease, and rejection is a
major complication. The expression of proinﬂammatory cytokines is related to graft loss, whereas anti-
inﬂammatory cytokines are associated with graft protection. The objective of this study is to evaluate the “in
situ” expression of cytokines T helper 1 (tumor necrosis factor α [TNF-α]), T helper 17 (interleukin 17 [IL-17]),
and regulatory T cell (transforming growth factor β [TGF-β]) and the expression of forkhead box P3 (FoxP3) in
allograft kidney. We evaluated in situ expression of cytokines in allograft kidney under rejection process by
indirect immunohistochemistry. Eighteen renal graft biopsies were from patients with episodes of rejection.
The in situ expression of IL-17, TNF-α, and TGF-β was signiﬁcantly higher in patients with acute rejection
when compared with the control group. In contrast, analysis of FoxP3 expression showed few positive cells in
patients with acute rejection compared with the control group. The results suggest that the expression of
proinﬂammatory cytokines (IL-17 and TNF-α) contributes to the mechanisms of kidney transplant rejection.
The increase in TGF-β expression might be an attempt to establish a process of immunoregulation or even to
induce higher production of IL-17. The last hypothesis is supported by the observation of a reduced expression
of FoxP3 and elevated levels of IL-17.ederal University of Triângulo
a –Minas Gerais – Brasil - CEP:
–5651.
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A kidney transplant is the best choice for the treatment of end-
stage kidney disease. Rejection of transplanted tissues involves the
interplay between mechanisms that maintain tolerance to the graft
and factors that promote rejection. Acute rejection continues to be
one of themost important causes of graft loss and involves the cellular
and/or humoral immune response [1]. Cellular rejection is character-
ized morphologically by the presence of mononuclear cells in the
interstitial, tubular, and glomerular compartments [1-3]. In contrast,
humoral rejection is associated with vascular involvement (vasculi-
tis), deposition of immunoglobulins (C4d deposition in peritubular
capillaries), and activation of the complement cascade [4-6].
T lymphocytes not only play an essential role in the initiation of the
cascade of mechanisms underlying rejection but also participate inmechanisms that maintain graft tolerance [7,8]. Naive CD4+ helper T
cells have been shown to develop into at least 4 types of committed
helper T cells, namely, T helper (Th) 1, Th2, Th17, and regulatory T
(Treg) cells [3,5,9]. Proinﬂammatory cytokines such as tumor necrosis
factor α (TNF-α) and interleukin (IL) 17 have been associated with an
increase in tissue injury and graft loss [10-12]. On the other hand,
anti-inﬂammatory cytokines such as transforming growth factor β
(TGF-β) and the transcription factor of Treg cells, forkhead box P3
(FoxP3), are associated with a better transplant prognosis because
they are involved in the control of injury during rejection [13,14].
Therefore, knowledge about the proﬁle of cytokines expressed in
cases of renal transplant rejection may help develop new methods to
improve monitoring of the immune response and contribute to a
more speciﬁc immunosuppression, thus preventing undesired side
effects of immunosuppressive therapy. Cytokines may be a useful
tool in clinical practice and may contribute to the production of
drugs and prophylactic and/or palliative treatment of rejection in
kidney transplant patients. Our objective was to evaluate the “in
situ” expression of cytokines Th1 (TNF-α), Th17 (IL-17), and Treg
(TGF-β) and the expression of FoxP3 in allograft kidney under
rejection process.
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2.1. Sample characterization
Eighteen renal graft biopsy fragments from patients undergoing
kidney transplantation at the Nephropathology Service, Universidade
Federal do Triângulo Mineiro, Uberaba, Minas Gerais, Brazil, were
studied. The diagnosis of rejection wasmade according to the Banff 07
classiﬁcation [15]. The basic characteristics of the patients are shown
in Table.
The control group was composed of 5 fragments from individuals
autopsied at the University Federal do Triângulo Mineiro, and these
tissues did not show any inﬂammation or pathologic process.
The study was approved by the Ethics Committee of Universidade
Federal do Triângulo Mineiro (protocol no. 1035).2.2. Immunohistochemistry
For immunohistochemistry, deparafﬁnized sections were treated
with 3% hydrogen peroxide in methanol for 10 minutes and incubated
for 30 minutes at 90°C for antigen retrieval. Nonspeciﬁc binding was
reduced by incubation of the sections in 2% bovine serum albumin for
30 minutes at room temperature. Next, the specimens were
individually incubated for 2 hours at 37°C with the following
anticytokine monoclonal antibodies diluted in 2% bovine serum
albumin before use: human anti-FoxP3 (1:20) (AF3240; R&D Systems,
Minneapolis, Minnesota), anti–IL-17 (1:20) (AF317-NA; R&D), anti–
TGF-β (1:20) (MAB240; R&D), and anti-TNF-α (1:100) (R&D). The
specimens were then incubated with secondary biotinylated anti-
mouse Ig, anti-rabbit Ig, and anti-goat Ig antibodies using the Link
System 002488 (Dako, Carpinteria, California) for 30 minutes at 37°C.
The sections were washed and incubated with the streptavidin-
peroxidase conjugate (Dako) for 30 minutes. For detection of C4d, the
slides were incubated with protein-blocking solution (Protein Block
Serum-free; Dako) for 30 minutes. Next, excess blocking solution was
removed, and the slides were incubated with anti-C4d antibody
(1:600; ALPCO, Salem, NH) overnight at 4°C. The slides were washed
with phosphate-buffered saline and incubated with the link antibody
(Advance HPR Link kit; Dako) for 30 minutes at room temperature.
The slides were again washed with phosphate-buffered saline and
incubated with the enzyme (Advance HPR Detection System; Dako)
for 30 minutes. The reaction was developed by incubation withTable
Characteristics and diagnosis of the patients
Biopsies Sex Age (y) Immunossupressor Diagnosis Banff 2007 C4d
B01-3844 M 52 AZ+ CYC + PRED CMAR III 0
B02-2226 M 37 MMF + CYC + PRED CMAR IB 0
B02-6384 F 40 MMF + PRED CMAR IIA 1
B03-0134 M 50 MMF + CYC + PRED CMAR IB 3
B03-2535 M 57 MMF + CYC + PRED CMAR IB 0
B06-2599 M 36 SOL + PROF CMAR IIA 1
B05-3667 M 35 PRED CMAR IB 2
B99-1166 M 32 CYC CMAR IB/AMAR II 2
BR060608 M 66 SOL + MMF BOR 1
B04-2803 M 53 CYC + MMF + PRED CMAR IB/AMAR 3
B04-3663 M 53 PRED CMAR IA/ AMAR II 3
B04-4241 M 55 PRED + AZ CMAR IA 1
B04-5083 M 69 MMF + CYC + PRED AMAR II 2
B04-5363 M 59 MMF + CYC + PRED AMAR II/ CMAR IA 2
B04-6110 M 52 PRED + RAPA BOR 0
B03-5562 M 37 PRED + RAPA + MMF CMAR IIA 1
B03-3197 F 29 PROF + PRED AMAR II 2
Abbreviations: M, male; F, female; MMF, mycophenolate mofetil; PRED, prednisone;
AZA, azathioprine; CYC, cyclosporine; SOL, Solu-medrol; PROF, Prograf; RAPA,
rapamycin; AMAR, antibody-mediated acute rejection; CMAR, cell-mediated acute
rejection; BOR, bordeline rejection.diaminobenzidine (Sigma, St Louis, Missouri). The sections were
counterstained with hematoxylin.
2.3. Morphometric analysis
Morphometric analysis consisted of the quantiﬁcation of the
number of immunopositive cells using images of the histologic
sections captured with a digital system and analyzed with the
Image J software (National Institutes of Health, USA). For this purpose,
each ﬁeld to be quantiﬁed was captured with a camera coupled to the
microscope and to a computer for digitalization of the image. The
number of cells in each ﬁeld and the area of each ﬁeld (0.091575
mm2) were determined. The density of positive cells is expressed as
the number of cells per square millimeter.
2.4. Analysis of C4d
The specimens were analyzed under a common light microscope
and classiﬁed according to the Banff 07 criteria [15]. C4d staining in
the peritubular capillaries of the cortex and/or medulla was graded as
follows according to the percentage of the area stained: C4d0, 0%,
negative; C4d1, 1% to 10%, minimal; C4d2, 10% to 50%, focal; and C4d3,
greater than 50%, diffuse.
2.5. Statistical analysis
Statistical analysis was performed using the GraphPad Prism 5.0
program (GraphPad Software, Inc, La Jolla, California). The Kolmogorov-
Smirnov test was used to determine the normal distribution of the
quantitative variables. The results are expressed as median and were
analyzed by the Mann-Whitney U test. Differences were considered to
be signiﬁcant when P b .05.
3. Results
In the present study, we evaluate IL-17 (Fig. 1A and B), TNF-α
(Fig. 1C and D), TGF-β (Fig. 1E and F), and FoxP3 (Fig. 1G and H) in situ
expression in the interstitium, glomerulus, tubular cells, and vessels in
control and rejection groups.
An important ﬁnding was that IL-17 and TNF-α expression were
signiﬁcantly higher in the interstitial compartment (IL-17 P = .002
and TNF-α P=.002) and in blood vessels (IL-17 P=.008 and TNF-α P=
.01), on cases of patientswith acute rejection comparedwith the control
group (Fig. 2A and B).
Similarly, we demonstrated that the TGF-β in situ expression was
signiﬁcantly higher in patients with acute rejection in the interstitial
compartment and the blood vessels as compared with the control
group (P = .002 and P = .008, respectively) (Fig. 2C).
However, when comparing the FoxP3 in situ expression, we
observed that patients with acute rejection expressed few positive
cells compared with the control group, mainly in the glomerular and
renal tubular cells and in the blood vessels (P=.001, P=.005, and P=
.02, respectively) (Fig. 2D).
4. Discussion
A new subpopulation of lymphocytes, called Th17, has been
discovered recently. These cells mainly produce IL-17 [11]. In view of
the pattern of expression of this cytokine in diseases characterized by
hyperactivation of the immune system, studies have investigated the
possible presence of IL-17 during episodes of graft rejection. In the
present study, expression of IL-17 was signiﬁcantly higher on acute
rejection in the renal interstitium and vessels. Vanaudenaerde et al
[16] detected elevated levels of IL-17 in bronchoalveolar lavage ﬂuid
during acute lung rejection. Similarly, increased IL-17 levels were
observed in the aqueous humor of patients with acute corneal graft
Fig. 1. Immunohistochemical in situ expression in vessels (1), interstitium (2), glomerulus (3), and tubular cells (4) in rejection and control groups: IL-17 (A and B), TNF-α (C and D),
TGF-β (E and F), and FoxP3 (G and H).
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demonstrated by an enzyme-linked immunosorbent assay was
associated with rejection, with elevated levels of the cytokine beingdetected in mononuclear inﬁltrate cells 2 days after transplantation.
The authors suggested that IL-17 might be a predictor of acute
rejection [17,18]. Tang et al [19] and Li et al [20] investigated the
Fig. 2. In situ expression of cytokines and transcription factor in different renal compartments: interstitium, glomerulus, tubular cells and vessels. A, IL-17; B, TNF-α; C, TGF-β; D,
FoxP3. The asterisk indicates statistically signiﬁcant differences (P b .05, Mann-Whitney U test).
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fusion protein in aorta and heart transplant recipients, respectively.
The authors demonstrated a delay or even the prevention of rejection.
In this study, the signiﬁcant increase of IL-17 was accompanied by
signiﬁcant increase of tumor necrosis factor in the same kidney
compartments. These results suggest that these proinﬂammatory
cytokines favor the process of acute rejection. Tumor necrosis factor α
has been shown to play an important role in the acute or chronic
rejection of various organs [13]. In a study investigating TNF-α and IL-
6 polymorphisms in recipients with allograft duration less than and
more than 10 years, there was a prevalence of subjects with the T1T1
genotype of TNF-α (low expression of TNF-α) and GG genotype of IL-6
(high expression of IL-6) among those with allograft duration more
than 10 years. No difference in allograft survival was observed for the
IL-2 and IL-4 promoter polymorphisms. The results of that study
suggest that the TNF-α −308 and the IL-6 −174 promoter poly-
morphisms may be the genetic factors inﬂuencing the renal allograft
survival [21].
In the present study, the number of positive cells for FoxP3 was
lower in all renal compartments when compared with control group.
Increased expression of IL-17 and TNF-α associated with a low
expression of Treg cells (FoxP3+) may result in a predominance of
Th17 lymphocytes [11]. According to some investigators, the level of
FoxP3 messenger RNA expressed in peripheral blood mononuclear
cells reﬂects the status of renal allografts and may be a noninvasive
biomarker for the diagnosis of acute rejection and chronic allograft
nephropathy. A recent studies support the potential functional role
of FoxP3 in tolerance in kidney transplants, suggesting that local
FoxP3-positive cells within the graft may induce a form of local
tolerance [22].
Despite the reduced FoxP3-positive cells in acute rejection, a larger
number of TGF-β–positive cells were observed in these patients.
Transforming growth factor β has been suggested to play a role in the
differentiation of naive lymphocytes into Th17 subpopulations [23]rather than in themaintenance of natural FoxP3+ Treg cells [24], a fact
supporting the intimate relationship between CD4+CD25+ regulatory
cells and Th17 effector cells. Under inﬂammatory conditions, these
Treg cells might be converted into Th17 subpopulations or even start
to produce IL-17 when stimulated by IL-6 and IL-2, thus demonstrat-
ing the plasticity of this lymphocyte subpopulation [25]. This fact
might explain the concomitant expression of IL-17 and TGF-β
observed in the present study, in which the latter cytokine would
not play an immunomodulatory role but rather induce the differen-
tiation and maintenance of the Th17 lymphocyte subpopulation. In
contrast, other studies demonstrated that high expression of TGF-β
during the initial stages of rejection could prevent chronic rejection,
indicating a possible role of this cytokine in the stimulation of Treg
cells [26].
Taken together, the present results suggest that the pattern of
proinﬂammatory cytokine (IL-17 and TNF-α) expression contributes
to the mechanisms of rejection of kidney transplants. The increase in
TGF-β expression might be an attempt to establish a process of
immunoregulation or even to induce a higher production of IL-17. The
last hypothesis is supported by the observation of a reduced
expression of FoxP3 and elevated levels of IL-17.References
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